DIA panel discusses collaboration to improve drug trials
Bizjournals – Jun 26, 2013
A system in which drug companies run head-to-head trials in much the same way as March Madness basketball brackets is one idea being considered to increase collaboration and ultimately reduce costs of clinical development.
Of the dozens of sessions at this year’s Drug Information Association annual meeting, taking place this week at the Boston Convention and Exhibition Center, one which cut right to the heart of the issues facing biotechs today was titled, “Collaborating to Streamline Drug Development: Are We Making Progress?”Douglas Peddicord, executive director of the Association of Clinical Research Organizations, framed the Wednesday morning panel discussion with a set of questions, including: Why does drug development cost too much and take too long, and what’s the low-hanging fruit that can be done to overcome the obstacles? Read More